In a phase II study, anti-BAFF therapy with belimumab was well-tolerated and had clear effects on B cells. 9 In a detailed analysis of peripheral blood B-cell subsets, belimumab induced dramatic ...

Vera Therapeutics, Inc.’s VERA share price has surged by 6.17%, which has investors questioning if this is right time to sell.